SIGA Technologies Q3 2020 Earnings Report
Key Takeaways
SIGA Technologies reported a substantial increase in revenue and net income for the third quarter of 2020. The company's performance was driven by the delivery of approximately 134,000 courses of oral TPOXX® to the Strategic National Stockpile (SNS). SIGA has also seen growth in their international business, with the Public Health Agency of Canada announcing their intent to purchase up to 33,300 courses of oral TPOXX®.
SIGA delivered approximately 134,000 courses of oral TPOXX® to the SNS in Q3 2020, recognizing $41.4 million in revenue.
The Public Health Agency of Canada (PHAC) intends to purchase up to 33,300 courses of oral TPOXX® within five years.
SIGA repurchased approximately 0.9 million shares of its common stock for $5.6 million during Q3 2020.
Total deliveries of oral TPOXX® under the 19C BARDA Contract are expected to total approximately 363,000 courses for the calendar year 2020, resulting in annual revenues of approximately $113 million.
SIGA Technologies
SIGA Technologies
SIGA Technologies Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income